PTC Therapeutics prices $500M convertible notes offering to refinance 2026 debt

Filed June 16, 2026 · Period ending June 15, 2026 · ~1 min read

Key Changes

• high

  Company priced $500 million of zero-coupon convertible senior notes due 2031, extending debt maturity and eliminating interest payments versus existing 1.5% notes.

  Item 8.01 verify on EDGAR →
• high

  Will use approximately $329 million of proceeds to repurchase $222 million principal of existing 2026 convertible notes through private negotiations, pushing out near-term debt maturities.

  Item 8.01 verify on EDGAR →
• medium

  Notes convert to common stock under certain conditions; initial purchasers received option to buy up to $50 million additional notes within 13 days.

  Item 8.01 verify on EDGAR →